AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00531180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Function Imaging
Description: Lung function imaging performed to provide information on how well the lungs work, how air moves into the lungs with breathing, and blood circulation into the lungs.
Study NCT06270745 — intervention group
Intervention type: DRUG
Intervention: indocyanine green
Description: Whether to use ICG to assess anastomotic perfusion during digestive system surgery
Study NCT02124850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT04807426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi Sensory stimulation exercises
Description: Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity is added by increasing speed of task performance. Conservative Management:Passive stretching exercises for paretic upper extremity muscles .Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set.
Study NCT04807426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Oriented Exercises
Description: Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set.
Study NCT04807426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented exercises and Multisensory stimulation Exercises
Description: Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set.
Study NCT04155450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extension Biased External Limb Loading Exercises
Description: Begin in the quadruped position and progress the intensity by~1. Flexing one upper extremity~2. Extending one lower extremity with a leg slide~3. Extending one lower extremity by lifting it off the mat~4. Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.~   Progress to prone position:~5. Extending one lower extremity~6. Extending both lower extremity
Study NCT04155450 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: McKenzie Extension Exercise Protocol
Description: Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing
Study NCT04155450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie Extension Exercise Protocol
Description: Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing
Study NCT04155450 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moist Heat
Description: Moist Heating for 10 minutes at lumbar spine in prone position using moist heat packs, heated via hydro-collator.
Study NCT04155450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moist Heat
Description: Moist Heating for 10 minutes at lumbar spine in prone position using moist heat packs, heated via hydro-collator.
Study NCT03737032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Theta Burst Stimulation
Description: For the sham of theta burst stimulation, the device providing Theta Burst Stimulation can be placed in the same position and turned on, creating a similar experience for the participant, without providing any neural stimulation. Sham TBS will be delivered with a Cool-B65 Active/Placebo Coil, which includes a sham setting, and MagLink research software.
Study NCT04955093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Technology to provide Heart Rate Variability Biofeedback
Study NCT04242654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Handheld fetal doppler ultrasound
Description: Handheld fetal doppler ultrasound will be used to assess heart rate in high-risk neonates.
Study NCT01694394 — intervention group
Intervention type: DEVICE
Intervention: Implantable Cardiac Monitor (Confirm ICM model 2102)
Description: Patients who meet the study criteria will be implanted with a St. Jude Medical Confirm Implantable Cardiac Monitor (Confirm ICM) model 2102 or other St. Jude Medical ICM with the same capabilities.
Study NCT06354543 — intervention group
Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components
Study NCT02124850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT04635735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
Study NCT00090285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Description: 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
Study NCT00090285 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
Study NCT04128592 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: diagnosing noisy breathing in infants and toddlers
Description: breath sampling and nasal mucus sampling to analyze biomarkers and breath sound analysis to diagnose noisy breathing.
Study NCT00975754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort pMDI HFA
Description: Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
Study NCT00975754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide pMDI HFA
Description: Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations
Study NCT00975754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort Repulses
Description: Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations
Study NCT00975754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort Turbohaler
Description: Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
Study NCT04906538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: all- inside anterior cruciate ligament reconstruction
Description: all- inside anterior cruciate ligament reconstruction with internal suture augmentation technique
Study NCT01458340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855
Description: Once daily
Study NCT01458340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily
Study NCT02499965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethyl Chloride Topical Aerosol Anesthetic
Description: Sprayed on the skin for 5-8 seconds immediately before IV cannulation
Study NCT02499965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nature's Tears Sterile Water
Description: Sprayed on the skin for 5-8 seconds immediately before IV cannulation
Study NCT02241018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD25 monoclonal antibody
Study NCT02241018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcineurin inhibitors
Study NCT02241018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Study NCT03295422 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RF ablation PVI alone
Description: A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins.
Study NCT03203343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operation - PIRS
Description: Operation by its known design for PIRS group
Study NCT03203343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operation - MARCY
Description: Operation by its known design for MARCY group
Study NCT04622228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
Study NCT04622228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of atezolizumab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT03295422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RF ablation PVI plus LPAW
Description: A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins. In addition, a roof and posterior line will be placed in the left atrium to achieve entrance and exit block on the posterior wall. Entry block will be confirmed by placing a circular mapping catheter in multiple locations along the posterior wall and confirming lack of presence of any local potentials. Exit block will be confirmed on the posterior wall with pacing at 10 amps from the ablation catheter at multiple locations within the box as well as all lines.
Study NCT02094105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy examination with iodine staining
Description: Endoscopy examination with Lugol's iodine staining and questionnaire once time and early treatment on precancerous lesions was undergone for the intervention group.
Study NCT04250805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients will receive Lidocaine during percutaneous gastrostomy under radiological guidance.
Study NCT04250805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Patients will receive Lidocaine during percutaneous gastrostomy under radiological guidance.
Study NCT04250805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Patients will receive Ropivacaine during percutaneous gastrostomy under radiological guidance.
Study NCT04622228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT02842853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular
Study NCT04622228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT02842853 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular
Study NCT04622228 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiation therapy (TRT)
Description: Participants will receive concurrent thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle.
Study NCT02762851 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: 0.5 ml dose injected intramuscularly
Study NCT03334214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS DGAT2Rx
Description: Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
Study NCT02762851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inactivated trivalent influenza vaccine
Description: 0.5 ml dose injected intramuscularly
Study NCT03922490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems Device PLUS debridement
Description: Lipogems is the name of the technology used to obtain stem cells from the abdomen, which will then be injected into the knee after knee arthroscopy.
Study NCT04369924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unidimensional Measurement-Based Care
Description: Youth and caregivers will complete a symptom rating scale every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
Study NCT03922490 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Debridement only
Description: Patients will undergo knee arthroscopy as a standard treatment for their condition but will not receive the fat-derived stem cell treatment nor will undergo any additional procedures.
Study NCT04369924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional Measurement-Based Care
Description: Youth and caregivers will complete battery of questionnaires covering multiple process and outcome domains every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
Study NCT03334214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 0.9%
Study NCT03713255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVB group
Description: Patients in this group will receive preoperative ultrasound-guided thoracic paravertebral block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
Study NCT03713255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTP block group
Description: Patients in this group will receive preoperative ultrasound-guided mid-point transverse process to pleura block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
Study NCT03025087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants will be getting hydroxychloroquine
Study NCT04618887 — intervention group
Intervention type: PROCEDURE
Intervention: pallidotomy
Description: deep brain nuclei lesion of GPi
Study NCT00635648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin acetate
Description: Intravenous (IV) caspofungin acetate 50 mg/day. Participants with esophageal candidiasis will be treated for at least 7 days and for at least 72 hours after symptoms resolve for a maximum of 28 days; participants with invasive candidiasis will have a 70 mg loading dose on study day 1 and will be treated for at least 14 days after the last positive culture of Candida from the blood or other normally sterile body site for a maximum of 60 days; these participants should also have improvement in clinical and radiographic signs of disease for at least 48 hours before completion of the study therapy.
Study NCT01585792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Study NCT01585792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Study NCT01038895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: tablet; 10 mg; od; 3 months
Study NCT01038895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: tablet; 300 mg; od; 3 months
Study NCT02722603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: 75 mg/ml gabapentin syrup
Study NCT02722603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol
Description: 100 mg/ml tramadol oral drops
Study NCT02722603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo tramadol
Description: placebo tramadol oral drops
Study NCT02722603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo gabapentin
Description: placebo gabapentin syrup
Study NCT01029483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: Ad libitum low carbohydrate diet (\<28g carbohydrate/day). Participants provided with research diet at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the food desired.
Study NCT04618887 — intervention group
Intervention type: PROCEDURE
Intervention: deep brain stimulation
Description: deep brain stimulation of GPi
Study NCT01455129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: 18 mcg tiotropium capsule, once daily, inhaled by HandiHaler, for 24 months
Study NCT01455129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, once daily, inhaled by HandiHaler
Study NCT03535571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salmon Protein Hydrolysate
Description: 4g of salmon protein hydrolysate per serving.
Study NCT03447197 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The use of extracorporeal circulation
Description: The use or not of extracorporeal circulation during the coronary artery bypass procedure.
Study NCT00558129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-STOP®
Description: Surgical implantation of X-STOP IPD device
Study NCT00558129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laminectomy
Description: Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
Study NCT01307605 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
Study NCT03713255 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Patients in this group will receive preoperative ultrasound-guided sham block with subcutaneous local anesthetic injection using lidocaine 1%, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
Study NCT03624998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive and physiatric testing
Description: Neuropsychological test battery and physiatric tests
Study NCT00003820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
Study NCT01982110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based smoking cessation
Description: Mindfulness based interventions are provided via a mobile phone application.
Study NCT01982110 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Smoking Cessation intervention
Description: Behavioral Smoking Cessation intervention is a behaviorally based intervention is provided via a mobile phone application.
Study NCT03528252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written advice LDL Cholesterol
Description: One A4 paper with written information on both sides